Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Lanchoney

Urology Bryn Mawr, PA Medical Doctor

NPI 1578666111 CMS profile 253484

245 Bryn Mawr Ave, Bryn Mawr, PA 19010

Open in the dashboard

General payments

$6,818

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Lanchoney of Bryn Mawr, PA is reported in the CMS Open Payments database as having received $6,818 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $840 34
2024 General $851 22
2023 General $908 28
2022 General $845 33
2021 General $918 41
2020 General $976 45
2019 General $1,480 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Lanchoney
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Thomas Lanchoney were reported at $840. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Thomas Lanchoney Urology median Middle half National median
2019 $1,480 $480 $147–$1,201 $163
2020 $976 $246 $87–$645 $114
2021 $918 $358 $111–$1,000 $132
2022 $845 $476 $143–$1,263 $149
2023 $908 $560 $168–$1,461 $160
2024 $851 $563 $170–$1,464 $164
2025 $840 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,099 50 payments
  2. Dendreon Pharmaceuticals LLC $789 17 payments
  3. Axonics Modulation Technologies, Inc. $767 13 payments
  4. AbbVie, Inc. $517 27 payments
  5. Janssen Biotech, Inc. $507 20 payments
  6. Teleflex LLC $485 16 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $296 9 payments
  8. Allergan Inc. $260 14 payments
  9. Pfizer Inc. $241 15 payments
  10. Ferring Pharmaceuticals Inc. $212 6 payments
  11. Other $1,645 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,364 257 payments
  2. Education $453 8 payments
Products named General payments · program years 2019–2025
  1. XTANDI $865 50 payments
  2. PROVENGE $789 17 payments
  3. Axonics $722 11 payments
  4. ERLEADA $515 21 payments
  5. BOTOX Botox Therapeutic $380 20 payments
  6. MYRBETRIQ $350 20 payments
  7. Bulkamid $313 4 payments
  8. BOTOX Urology $312 15 payments
  9. Xofigo $250 7 payments
  10. UROLIFT $212 8 payments
  11. Other $2,550 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

3,760

Median for Urology: 1,053

Drug cost

$1,261,108

Median for Urology: $101,464

Branded share of claims

31.9%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orgovyx Relugolix Brand 189 $480,093
Xtandi Enzalutamide Brand 29 $355,997
Abiraterone Acetate Generic 66 $176,154
Myrbetriq Mirabegron Brand 218 $136,652
Tamsulosin Hcl Generic 1,232 $20,703
Gemtesa Vibegron Brand 24 $16,525
Silodosin Generic 153 $12,226
Potassium Citrate Er Potassium Citrate Brand 74 $10,491
Mirabegron Er Mirabegron Brand 14 $9,046
Methenamine Hippurate Generic 81 $6,259

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$358,703

Of which drugs: $36,449

Medicare patients

1,429

Average age 76

Services billed

16,020

248 women, 1,181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 41%
Cancer 30%
Diabetes 25%
Chronic kidney disease 25%
Atrial fibrillation 24%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Bcg live intravesical instillation, 1 mg J9030 Office 11 1,750 $3,789

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $216
$216 — —
BOTOX
  • AbbVie, Inc. $194
$194 — —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $33
$33 — —
ERLEADA
  • Janssen Biotech, Inc. $29
$29 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $23
$23 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record